Takeaways From TransATAC Trial on Comparing Prognostic Signatures

T-DM1 was tolerable in HER2-positive biliary tract adenocarcinoma but did not significantly improve progression-free survival.

In this episode of Targeted Talks, Sanjay K. Juneja, MD, discusses the exciting advancements of artificial intelligence in 2024.

Bevacizumab's survival benefits in CRC patients persist for about 2 years after starting treatment.

In season 3, episode 3 of Targeted Talks, William J. Gradishar, MD, discusses the latest version of the NCCN Clinical Practice Guideline for managing early-stage breast cancer.

A "watch and wait" strategy after total neoadjuvant therapy showed similar outcomes and safety to total mesorectal in stage II/III rectal cancer.

Early palliative care reduces invasive interventions and enhances comfort at EOL for CRC patients, according to real-world study results.